

An Overview of Nanoparticle-Based Approaches for Targeted Therapy in Cardiovascular Diseases

Govind Sharma^{1*}, Vinay Sagar Verma¹

²KIPS, Shri Shankaracharya Professional Univesity, Bhilai, Chhattisgarh, India,
491001

*Corresponding Author E-mail: govindsharma10aug@gmail.com

Abstract:

Nanoparticle-based medicate conveyance frameworks, moreover known as nano-DDSs, show a promising approach to focused on treatment within the treatment of cardiovascular illnesses (CVDs), which incorporate heart disappointment, arrhythmia, atherosclerosis, and myocardial dead tissue. A diagram of the use of nanoparticles within the conclusion and treatment of cardiovascular infection (CVD) is displayed in this work. The nanoparticles that are examined incorporate natural and inorganic nanoparticles, as well as multifunctional nanoparticles. Nano-DDSs have the capacity to move forward restorative results whereas simultaneously minimising side responses and focusing on particular zones. Usually fulfilled by precisely conveying solutions to atherosclerotic plaques and encompassing tissues. In expansion, these innovations make strides demonstrative capabilities of imaging modalities counting attractive reverberation imaging (MRI) and computed tomography (CT). The application of nanotechnology permits for the determination of issues such as non-specific cytotoxicity, destitute dissolvability, and restricted bioavailability. Both the plausibility of custom fitted sedate conveyance and the advance that has been made in cardiovascular nanomedicine have the potential to upgrade quiet results significantly.

Keywords: cardiovascular diseases, nanoparticle-based drug delivery, nanomedicine, targeted therapy, diagnosis, multifunctional nanoparticle

I. INTRODUCTION

Cardiovascular breakdown, arrhythmia, fringe blood vessel infection, profound vein

apoplexy, coronary illness, myocardial infarction (MI), provocative coronary illness, and other cardiovascular diseases (CVDs) are driving reasons for death

around the world. As per information from the World Heart League, 17.3 million passings yearly are credited to CVDs.[7] Throughout the following decade, it is guessed that the quantity of passings will ascend because of an expansion in the pervasiveness of CVD risk factors, including stoutness, high non-HDL cholesterol, diabetes, hypertension, tobacco use, absence of active work, horrible eating routine, and a maturing populace. By 2030, it's guessed that 23.6 million individuals will kick the bucket from CVDs every year.[14] In light of the seriousness and hazard order of the patient, different medicines for CVDs are picked. All CVD treatment regimens mean to further develop blood stream and lessen tissue harm to decrease the deficiency of cardiomyocytes and grow contractile region.[8] Medical procedure is ordinarily used to eliminate blood clumps, embed fake cardiovascular pacemakers in circumstances of arrhythmia, and right neurotic natural heart changes in instances of extreme CVD. It ought to shock no one that adhering to a standard medication routine can challenge; by and large, the course of treatment requires long lasting drug.[22]

For most of patients with hypercholesterolemia, statin medicine is informed as the underlying course regarding treatment.[17] Statin treatment is compelling in bringing down cholesterol levels as well as in decreasing irritation, separating blood clumps, and upgrading endothelial capability.[16] The most famous prescription for auxiliary CVD counteraction is headache medicine. Adrenergic receptor bad guys, as β -

blockers, are able to do powerfully restricting thoughtful sensitivity and cardiotoxicity.[9] Thus, β -blockers are additionally suggested as the underlying line of treatment for CVDs and atrial fibrillation; in any case, patients with hypertension shouldn't utilize them. The favored prescriptions for the treatment of cardiovascular breakdown, coronary supply route sickness, MI, and hypertension are presently angiotensin changing over chemical inhibitors and angiotensin II receptor blockers.[18] Neprilysin inhibitors and angiotensin II receptor blockers keep individuals with cardiovascular breakdown from initiating the renin-angiotensin-aldosterone framework and forestall enkephalinase from expanding the measures of specific endogenous vasoactive peptides. Sacubitril-valsartan plays a demonstrated part in treating patients with cardiovascular breakdown who have decreased or safeguarded discharge division, as exhibited by the Worldview HF and PARAGON-HF preliminaries.[10] The restorative impacts of pharmacotherapy are below average notwithstanding the beyond a decade of huge headways in medicines; these reasons incorporate vague cytotoxicity, unfortunate dissolvability and retention, first pass digestion, unfortunate biocompatibility, and low bioavailability of current cardiovascular medications.[23]

Nanotechnology is an interdisciplinary field of study that includes science, medication, and hardware. The possibility of the "enchantment projectile" was first proposed by prestigious German bacteriologist Paul Ehrlich toward the

finish of the 1800s. [11] In the former many years, nanomedicine, otherwise called nano-biotechnology, has accumulated worldwide consideration as one of the quickest developing and most dynamic areas of nanotechnology research. The qualities and blend strategies of particular nanomaterials decide the structures, sizes, designs, and transport elements of nanoparticle-based drug conveyance frameworks (nano-DDSs), from which ideal nanocarriers are made and designed.[19] To exactly convey drugs to

atherosclerotic plaques, nanoparticles (NPs) utilize their better porousness and maintenance impact.[12] This prompts better helpful advantages and less tissue harm.[20] Moreover, nano-DDSs show incredible commitment for improving medicine viability, expanding the term of medication activity, upgrading bioavailability, specifically or effectively focusing on, bringing down drug opposition, and limiting antagonistic medication reactions.[21]




Figure 1: Cardiovascular medication delivery systems using nanoparticles

a) Nanoparticles

Nanoparticles (NPs) are either inorganic or common plants that are commonly beneath 100 nm in one perspective. Whereas inorganic NPs are comprised of a scope of minute assessed structures like quantum spots, mesoporous silicon, graphene, carbon nanotubes, metals, or metal oxides, common NPs are comprised of diverse

biodegradable materials like lipids, liposomes or micelles, proteins, dendrimers, polymeric vesicles, or hyaluronic destructive.[2] Metal-natural structures, regularly insinuated to as penetrable coordination polymers, are exceptionally penetrable and glasslike polymers comprised of course bonds meddle characteristic ligands to metal particles or metal bunches. Polyethylene

glycol completely wraps the surfaces of metal-natural structure nanomaterials, reducing the secure framework's opportunity.[13] All through the course of later a long time, sedate movement inquire about has focused in thought by and large on

the properties of nanoparticles (NPs) since of their estimate and shape, interconnected macropores, tunable porosity, compound sythesis, and straightforward surface functionalization. Utilizing circling cells' natural capacity to prevail nanomaterials' immunogenicity, the blend of cell transporter and nano-drug transport

development to boot rapidly obtaining notoriety.[15] For occasion, NPs were utilized to stack rapamycin by covering themselves within the movies of ruddy platelets or platelets. It is routinely known that biomimetic NPs have a favored therapeutic impact in vivo over conventional nano-drug transport methodologies and can thwart macrophage phagocytosis in vitro. By and by, liposomes, micelles, dendrimers, polymer NPs, and metal NPs are the foremost for the most part utilized and broad nanomaterials within the conclusion and treatment of CVDs. [1]




Figure 2: Types of Nanoparticles

Nanoparticle-based approaches for targeted therapy in cardiovascular diseases (CVDs) represent a promising and innovative strategy to improve the diagnosis and treatment of various heart-related conditions such as heart failure, atherosclerosis, myocardial infarction, and arrhythmia.[4] These approaches utilize

nanoparticles—tiny particles with unique physical and chemical properties—to deliver therapeutic agents directly to affected tissues and atherosclerotic plaques. By enabling precise targeting, nanoparticles can enhance the efficacy of existing drugs, reduce side effects, and improve patient outcomes. Additionally, nanoparticle-based

drug delivery systems can be customized in size, shape, and composition to cater to specific treatment needs, while also supporting advanced diagnostic techniques such as MRI and CT imaging. As cardiovascular diseases continue to pose significant health risks worldwide, the application of nanotechnology in cardiovascular medicine offers a pathway to more effective and personalized care for patients.[3]

II. OBJECTIVES OF THE STUDY

- To Explore Nanoparticle-Based Drug Delivery Systems.
- To Investigate the use of nanoparticles in diagnosing and treating various cardiovascular conditions.
- To Explore how nanoparticles are used in medical imaging techniques for CVD diagnosis.
- To Examine how nanoparticles can achieve targeted drug delivery in specific cardiovascular pathologies.

III. NANOPARTICLES AND CVD

The clinical business has utilized nanotechnology to give creative stages to conclusion and treatment that can supplant regular methods. Cardiovascular nanomedicine (CVN) zeroed in for the most part on imaginative clarifications for the deficiencies of existing CVD treatments. The first objective of CVN's nanosystems was to work on the bioavailability, security, and wellbeing of as of now supported meds. Nanomaterials contrast from standard materials in their physicochemical attributes, for example, their high surface energy and improved surface region to volume proportion, which influence natural action and protein grip. Consequently, the controlled and designated drug organization of various utilitarian parts pointed toward overseeing irregularities of lipid digestion and different diseases related with CVD is made conceivable by nanotechnology, which offers a protected and viable stage.[5]




Figure 3: Types of nanoparticles used in cardiovascular disease

Many researchers are actively working on developing nano-drug carrier systems for CVD detection and treatment. In order to combat atherosclerosis and other CVDs, several medicines can be encapsulated in nanoparticles. There are two uses for encapsulation in nanomedicine.[6] First, it protects the environment in vivo or off-target characteristics from hazardous medications by verifying that the drug's release is regulated by the material's features and that its surface qualities allow for targeted delivery of the drug to the affected area. Additionally, the encapsulation technique protects pharmaceuticals from unwanted changes and deterioration. Surface functionalization is additionally the best method for focusing on unambiguous parts of plaque or stay away from safe framework and leeway by the body. The essential reason of this approach is a high proportion of surface region to volume. The principal moieties added to nanoparticles (antibodies,

peptides, aptamers, or little atoms) that are explicit for components in plaque and PEGylation — which discusses dependability and secrecy in vivo — are known as focusing on ligands.

Nanoparticles have demonstrated encouraging results and have a variety of diagnostic applications during CVD. Magnetically-property iron oxide nanoparticles were employed in magnetic resonance imaging (MRI) in the early 1990s to treat vascular disorders. High-density lipoprotein-like and perfluorocarbon emulsion nanoparticles containing gadolinium have been employed as MRI contrast agents for imaging applications since the late 1990s and early 2000s. Table 1 lists the nanoparticles that are applied to atherosclerosis and are mostly employed in multimodal imaging, positron emission tomography, computed tomography (CT), MRI, and biomarker detection.

Table 1: Nanoparticle for cardiovascular disease

Imaging mode	Nanoparticle	Target	Disease
MRI	Lipid nanoparticles in solid form	Platelet	Atherosclerosis
MRI	$\alpha_v\beta_3$ -targeted paramagnetic nanoparticles	$\alpha_v\beta_3$ -integrin	Atherosclerosis
MRI	Lipoprotein-like magnetic nanostructures with a high density (HDL-MNS)	Macrophage	Atherosclerosis
Fluorescence imaging	Hyaluronic acid–polypyrrole nanoparticles loaded with drugs (HA–PPyNPs)	Macrophage	Atherosclerosis
CT	Gold nanorods	Macrophage	Atherosclerosis

Multimodality molecular imaging and fascinating clinical diagnosis aspects are features of molecular imaging based on nanotechnology. Fluorescence-based molecular imaging techniques offer diverse target detection, good sensitivity, and excellent resolution in both preclinical and clinical CVD. The use of (NIRF) in cardiovascular disease (CVD) imaging has drawn a lot of attention recently. Because these probes have a higher penetration power and are safer, they are widely employed in in vivo imaging systems. These days, NIRF can be used to get optical imaging of blood arteries using a variety of nano-drug carriers, including liposomes and metal or non-metallic nanoparticles.

IV. POLYMERIC NANOPARTICLES AND CVD

The most common class of materials used to make nanoparticles is polymers. Since the properties of polymeric nanoparticles can be acclimated to control their hydrophobicity, degradability, and conceivable reabsorption inside the body, their creation is essential. Since polymers are less unsafe than metals and can functionalize an objective by giving synthetically dynamic locales, they are utilized widely. Polymers can be regular or

fabricated. Starches, cellulose, plastic, chitosan, gelatin, alginate, and proteins are instances of regular polymers. Enormous scope creation of polymeric biodegradable nano-drug conveyance frameworks utilizes engineered polymers, for example, polylactic acid (PLA), (PLGA), polyvinyl imine, polycaprolactone, and polyvinyl alcohol. Nanospheres or nanocapsules are run of the mill types of polymeric nanoparticles. Not at all like drugs or other strong particles infused into a polymeric grid, the restorative component of nanocapsules is contained inside a polymeric container shell. They, by and large, are more affordable and simpler to deliver and increase than liposomes with longer security profiles. While dealing with conditions like disease, neurological sicknesses, cardiovascular infirmities, and so forth, these nanoparticles convey the drug to an exact area and at an exact dose. Polymer nanoparticles have been utilized as prescription transporters in the improvement of nanosystems for the treatment of atherosclerosis. Novel and further developed restorative options are expected to analyze atherosclerosis and decrease the gamble of major cardiovascular issues in patients who have gotten standard consideration.

Table 2: Nano-sized materials as drug delivery systems for CVDs.

Medications for the management of CVDs	Types of nanocarriers	Biological Functions
The enzyme streptokinase	Naked liposomes and water-soluble double emulsion polymer	Activators of plasminogen
Phenolodisolone acetate	Liposomal nanoparticles coated with PEG	The illness atherosclerosis

Levosimendan (Simdax)	Gold nanoparticles	An inotropic drug that improves heart failure patients' myocardial contractility
Quercetin	Polymeric superparamagnetic nano-silica	Antioxidant agent: utilised to treat related CVD, including atherosclerosis
Atrial natriuretic peptide	Biodegradable porous silicon	used to treat individuals with ischemic heart disease in the damaged myocardium
Heparin and glutathione	Poly (lactide-co-glycolide) (PLGA)	Vascular treatment uses antioxidants and anticoagulants.
Hirudine	Dendrimer	anticoagulant and antithrombotic medication
Pioglitazone	PLGA nanoparticle	Plaque stability and monocyte/macrophage polarisation in the murine model of plaque rupture

V. APPLICATION OF NANOPARTICLES IN ATHEROSCLEROSIS

Nanotechnology is a valuable device for treating atherosclerosis since it can move different naturally dynamic go between from nanocarriers to the vascular wall, which assists with bringing down key atherogenesis changes including intimal hyperplasia. While treating hyperlipidemia, curcumin nanoemulsion embodiment has shown a more prominent potential for bringing down cholesterol than pravastatin. On the outer layer of the nanovesicles, an oligonucleotide was functionalized to target provocative macrophages, prompting a huge decrease in cytotoxicity in muscle

cells. The main statin to be utilized in clinical practice was lipophilic drug lovastatin (LVT).

The destabilization and burst of the atherosclerotic plaque are altogether impacted by monocyte fiery movement. Plaque burst is forestalled by following up on the site of irritation through the delivery of pitavastatin-stacked nanoparticles. Moreover, to build the restorative proficiency of pitavastatin, an exceptional drug delivery system made of PLGA was brought into monocytes, endothelial cells, and vascular smooth muscle cells.

VI. APPLICATION OF NANOPARTICLES FOR THE TREATMENT OF MYOCARDIAL INFARCTION

Heart hurt brought almost by too duplication and missing constrain with respects to self-mending cardiomyocytes are oftentimes irreversible. To treat AMI, an collection of injectable biomaterials were made. A few of them are delivered utilizing nanofibers, which can be utilized to donate medicate. One demonstrate is the injectable hydrogel RAD16-II (hydrogels of self-collecting peptides), which is basically arranged for intramyocardial transport and is utilized to convey vascular endothelial development figure (VEGF). An unique way to bargain with treating myocardial ischemia-reperfusion damage in patients with AMI is reperfusion treatment utilizing irbesartan-stacked nanoparticles, which are a fundamental awful fellow of the angiotensin II sort 1 receptor.

VI. Utilising nanoparticles to treat stroke patients

The solutions atorvastatin and rosuvastatin, which both truly reduce neuronal cell passing and have outstandingly too porousness through the blood-cerebrum obstacle within the central tactile framework — a key arrange that chooses their reasonability for treating ischemic stroke — diffuse all the more quickly since of statin nanoparticulate transporter systems.

VII. NANOPARTICLES FOR PULMONARY HYPERTENSION AND CARDIOMYOPATHY

Because of pulmonary arterial course blood stream restriction, (PAH) is a lethal illness. One of the principal reasons of death for

PAH patients is correct cardiovascular breakdown, which is welcomed on by this condition's right ventricular hypertrophy, hyperplasia, and fibrosis. The conventional pharmacological medicines for PAH depend on controlling vascular tone, for the most part by zeroing in on flagging pathways such nitric oxide, endothelin, and prostacyclin (PGI₂). In any case, non-adherence to medication and unfavorable impacts reduce their complete remedial potential, and PAH stays a deadly disease for various people. To resolve these issues, various state of the art helpful methodologies for PAH are being investigated, for example, nanoparticle-mediated drug delivery systems (nano-DDS). While treating pulmonary conditions, NanoDDS might increment adequacy while bringing down unfriendly drug responses.

The impacts of nanoparticles stacked with PGI₂ simple, phosphodiesterase type-5 (PDE5) inhibitors, oligonucleotides, pitavastatin, imatinib, rapamycin, and fasudil were recorded in both in vitro and in vivo explores. According to certain reports, the intravenous organization of PLA nanoparticles exemplified with monomethoxy poly(ethylene glycol)-poly(lactide) and beraprost, a simple of prostacyclin, blocks the copolymer shield against right ventricular hypertrophy and pulmonary arterial redesigning brought about by monocrotaline (MCT). Consistently, beraprost nanoparticles were infused intravenously to forestall right ventricular hypertrophy and hypoxia-instigated pulmonary arterial renovating.

VIII. Small interfering RNA used in CVDs

Small interfering RNAs (siRNAs) and antisense oligonucleotides are instances of oligonucleotides that are synthetically combined and can work straightforwardly, successively conditionally, on an objective quality, making them an ideal drug. Since RNA impedance can keep grafting varieties and freaks from being communicated, designated siRNA is useful for proteins that can't be picked apart. Thus, siRNA has extraordinary remedial potential for treating many ailments. Following the underlying clinical preliminaries with intraocularly managed siRNA against VEGF, the utilization of siRNA is presently showing incredible commitment and is overall completely researched for the production of drugs connected to siRNA. It is pivotal to set up a reasonable siRNA drug delivery system (DDS). Because of its hydrophilic and polyvalent anionic nature, siRNA isn't very much collected in an objective tissue since it isn't promptly consumed by cells and is promptly separated by blood nucleases. Lipid nanoparticles (LNPs) certainly stand out enough to be noticed as a promising transporter for siRNA delivery. For the therapy of atherosclerosis and persistent irritation in CVD, systemic organization of siRNA-exemplified LNPs with long haul quality hushing impacts more than a 10-day time frame was viewed as proper.

IX. TARGETED DRUG DELIVERY

The essential focal point of nano-drug delivery systems during their underlying progressive phases is on malignant growth

conclusion and treatment. Current examinations, nonetheless, recommend that lesioned cells/tissues of CVDs might be more straightforward to focus than tissues with a few physiological hindrances encompassing a growth. By changing pH, temperature, light, ultrasound, or natural catalyst, one can broaden and control the rate and capability of designated nano-carrier prescriptions. They were viewed as useful for both treating and forestalling restenosis, as well concerning coordinating nanoparticles with different bio-actual qualities towards the infected areas of interest. The drug-loaded nanoparticles should get away from the resistant system, target specific cells or tissues, and deliver the restorative substance they have been stacked with to move drugs to chosen region of the body really. High porousness and high maintenance (EPR) impacts empower latent focusing of nanoparticles to the objective spot. EPR impact isn't simply pertinent to growths yet can likewise be utilized to CVDs. For example, the headway of atherosclerosis, which brings about expanded vascular penetrability, is simply like strong cancers. Drugs can be conveyed from the lumen side of the plaque to its inside utilizing nano-drug delivery systems on account of vascular endothelial porousness. In the wake of being ingested by the nano-drug transporters and entering the circulation system, the provocative cells (monocytes or macrophages) were moved to the site of plaque irritation, which permitted the prescriptions to be conveyed in an alternate technique.

Energetic centering on highlights the utilitarian alter of nano-drug conveyance

frameworks with various destinations to enable the medicine to reach at a predefined spot. A down to earth gathering or energetic fabric that expressly collaborates with debilitated tissues/cells into the exterior of the nano-drug transporter was included to the nanoparticles to progress centering on. Through rebellious like endocytosis, phagocytosis, and pinocytosis, nanoparticles can be devoured by cells. They can be dispensed with from tissues and organs adequately long to be taken advantage of for unequivocal nanoscale capabilities, counting as updated clinical imaging, assigned conveyance to murder wiped out cells, and assigned medicate conveyance.

X. MULTIFUNCTIONAL NANOPARTICLES FOR CVD

Since they might go through extravascular and intravascular systems, nanoparticles are ideal for the designated delivery of meds and imaging specialists. Their common multifunctionality has exhibited a lot of commitment as a stage for custom-made drug organization. The improvement of multifunctional nanoparticles (MFNPs) as drug transporters has prompted various novel methodologies in customized medication, imaging, and diagnostics for the treatment of CVDs. Various CVD sorts are being identified, pictured, and treated with nanoparticles. Considering that these MFNPs have a critical surface region to-volume proportion and a minuscule size, they give a few benefits over conventional medication. These benefits remember further developed poisonousness profile and a decrease for measurement. These

meds' intracellular assimilation is upgraded by their high surface region, which likewise raises their dissolvability and pace of disintegration. The nano-drug is typified by the drug transporter, which shields it from outside impacts. Nanoparticles of drug can undoubtedly penetrate through cell layers because of their small size. The delivery of the helpful burden at the ideal site is made conceivable by the controlled arrival of nanomedicines. Since MFNPs emphatically affect perception, conclusion, and ailment treatment, they are utilized to recognize and treat CVD. In polysaccharide-based nanomaterials, there have been striking progressions towards multifunctional and complex controlled discharge systems. This addresses a huge step towards theranostics and regenerative medication with worked on mechanical properties, security profiles, and helpful productivity.

XI. Conclusion

The natural utilization of nanotechnology is progressively vital for the treatment of CVD and significantly affects medication with regards to checking, diagnosing, forestalling, mending, or fixing sicknesses and injured tissues in organic systems. Regardless, bringing issues to light and propelling the utilization of nanotechnology is as yet vital. On account of their interesting physicochemical and organic qualities, polysaccharide-based nanoparticles assume a significant part as transporters of numerous restorative drugs. Different drug delivery systems have been used in light of the favored treatment specialist and illness stage. Various little compounds as well as, more as of late,

DNA, siRNA, peptides, and proteins make up remedial specialists. Drug delivery systems, which include liposomes and nanoparticles, are heavily dependent on the intrinsic qualities of pharmaceuticals, including their solubility, molecular weight, and intended therapeutic use. From this angle, using nanotechnology as a capable and innovative tool to manage CVD is appealing. Increasing treatment efficacy and reducing negative effects from the freely delivered medication are two important goals of nanotherapy. An overview of the application of nanotechnology in CVD is provided by this review.

XII. FUTURE SCOPE

The potential of nanoparticle-based targeted therapy techniques for cardiovascular diseases (CVDs) is contingent upon the advancement of increasingly complex and multifunctional nanoparticles, which can enhance the conditions' diagnosis, treatment, and monitoring. The development of nanoparticles with improved targeting properties could result from advances in nanotechnology and allow for more precise drug delivery to damaged tissues with fewer systemic side effects. Subsequent investigations may also delve into the potential of nanoparticles in the context of regenerative medicine, with the aim of facilitating cardiac tissue restoration and recuperation following myocardial infarction. Furthermore, the treatment of CVD may be completely changed by fusing nanotechnology with other cutting-edge disciplines like gene therapy and

immunotherapy. With the increasing comprehension of the molecular mechanisms underlying CVDs, it may be possible to create nanoparticles that specifically target biomarkers or pathways linked to the advancement of the illness. All things considered, the application of nanoparticle-based techniques in cardiovascular medicine shows promise for more individualised, efficient, and minimally invasive treatments that will enhance patient outcomes and quality of life.

REFERENCES

- [1] Clark H. NCDs: a challenge to sustainable human development. *Lancet* 2013;381:510–11.
- [2] World Health Organization Cardiovascular diseases (CVDs), Geneva: World Health Organization; 2021. [https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-\(cvds\)](https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)). [accessed 11-06-2021].
- [3] Chandarana M, Curtis A, Hoskins C. The use of nanotechnology in cardiovascular disease. *Appl Nanosci* 2018;8:1607–19.
- [4] Zhao Y, Ransom JF, Li A, Vedantham V, von Drehle M, Muth AN, et al. Dysregulation of cardiogenesis, cardiac conduction, and cell cycle in mice lacking miRNA-1-2. *Cell* 2007;129:303–17.
- [5] Laflamme MA, Murry CE. Heart regeneration. *Nature* 2011;473:326–35.
- [6] Prajnamitra RP, Chen HC, Lin CJ, Chen LL, Hsieh PC. Nanotechnology approaches

in tackling cardiovascular diseases. *Molecules* 2019;24:2017.

[7] Chronic heart failure in adults: diagnosis and management. NICE guideline [NG106], <https://www.nice.org.uk/guidance/ng106>; [accessed 12-09-2018]

[8] Mauricio MD, Guerra-Ojeda S, Marchio P, Valles SL, Aldasoro M, Escribano-Lopez I, et al. Nanoparticles in medicine: A focus on vascular oxidative stress. *Oxid Med Cell Longev* 2018;2018:6231482.

[9] Radomska A, Leszczyszyn J, Radomski MW. The nanopharmacology and nanotoxicology of nanomaterials: new opportunities and challenges. *Adv Clin Exp Med Off Organ Wroclaw Med Univ* 2016;25:151–62.

[10] Nabel EG, Braunwald E. A tale of coronary artery disease and myocardial infarction. *N Engl J Med* 2012;366:54–63.

[11] Wang AZ, Langer R, Farokhzad OC. Nanoparticle delivery of cancer drugs. *Annu Rev Med* 2012;63:185–98.

[12] Farokhzad OC, Langer R. Impact of nanotechnology on drug delivery. *ACS Nano* 2009;27:16–20.

[13] Dizaj SM, Rad AA, Safaei N, Salatin S, Ahmadian E, Sharifi S, et al. The application of nanomaterials in cardiovascular diseases: A review on drugs and devices. *J Pharm Pharm Sci* 2019;22:501–15.

[14] Rhee JW, Wu JC. Advances in nanotechnology for the management of

coronary artery disease. *Trends Cardiovasc Med* 2013;23:39–45.

[15] DiStasio N, Lehoux S, Khademhosseini A, Tabrizian M. The multifaceted uses and therapeutic advantages of nanoparticles for atherosclerosis research. *Materials (Basel)* 2018;8(11):754. .

[16] Weissleder R, Elizondo G, Wittenberg J, Rabito CA, Bengel HH, Josephson L. Ultrasmall superparamagnetic iron oxide: characterization of a new class of contrast agents for MR imaging. *Radiology* 1990;175:489–93.

[17] Lanza GM, Lorenz CH, Fischer SE, Scott MJ, Cacheris WP, Kaufmann RJ, et al. Enhanced detection of thrombi with a novel fibrin-targeted magnetic resonance imaging agent. *Acad Radiol* 1998;5(1):S173–6 Suppl..

[18] Yu X, Song SK, Chen J, Scott MJ, Fuhrhop RJ, Hall CS, et al. High-resolution MRI characterization of human thrombus using a novel fibrin-targeted paramagnetic nanoparticle contrast agent. *Magn Reson Med* 2000;44:867–72.

[19] Winter PM, Morawski AM, Caruthers SD, Fuhrhop RW, Zhang H, Williams TA, et al. Molecular imaging of angiogenesis in early-stage atherosclerosis with $\alpha\beta 3$ -integrin-targeted nanoparticles. *Circulation* 2003;108:2270–4.

[20] Flacke S, Fischer S, Scott MJ, Fuhrhop RJ, Allen JS, McLean M, et al. Novel MRI contrast agent for molecular imaging of fibrin implications for detecting vulnerable plaques. *Circulation* 2001;104:1280–5.

[21] Smith S. C., Jr, Smith A., Collins R., Ferrari D. R., Jr, Holmes S., Logstrup D. V., et al. (2012). Our time: A call to save preventable death from cardiovascular disease (heart disease and stroke). *Glob. Heart* 7 (23), 297–305. 10.1161/CIR.0b013e318267e99f10.1016/j.ghart.2012.08.002

[22] Iafisco M., Alogna A., Miragoli M., Catalucci D. (2019). Cardiovascular nanomedicine: The route ahead. *Nanomedicine (Lond)* 14 (18), 2391–2394. 10.2217/nmm-2019-0228

[23] Yusuf S., Joseph P., Rangarajan S., Islam S., Mente A., Hystad P., et al. (2020). Modifiable risk factors, cardiovascular disease, and mortality in 155 722 individuals from 21 high-income, middle-income, and low-income countries (PURE): A prospective cohort study. *Lancet* 395 (10226), 795–808. 10.1016/S0140-6736(19)32008-2